Sonic Healthcare Limited (ASX:SHL)

Market Cap	9.26B -21.2%
Revenue (ttm)	10.87B +12.7%
Net Income	608.29M +18.4%
EPS	1.23 +15.3%
Shares Out	494.14M
PE Ratio	15.23
Forward PE	15.39
Dividend	1.08 (5.12%)
Ex-Dividend Date	Sep 2, 2026

Volume	3,495,756
Open	18.40
Previous Close	18.73
Day's Range	18.40 - 19.30
52-Week Range	18.26 - 24.27
Beta	0.59
Analysts	Hold
Price Target	22.51 (+16.63%)
Earnings Date	Nov 18, 2026

About Sonic Healthcare

Sonic Healthcare Limited offers medical diagnostic services, and administrative services and facilities to medical practitioners in Australia, the United States, Germany, and internationally. The company provides laboratory medicine/pathology testing services, such as biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal testing, toxicology, and ancillary functions; and radiology services, including magnetic resonance imaging, computed tomography (CT), ultrasound, X-ray, ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1934
• Employees: 45,000
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: SHL

Financial Performance

In fiscal year 2026, Sonic Healthcare's revenue was 10.87 billion, an increase of 12.67% compared to the previous year's 9.65 billion. Earnings were 608.29 million, an increase of 18.44%.

Analyst Summary

According to 16 analysts, the average rating for SHL stock is "Hold." The 12-month stock price target is $22.51, which is an increase of 16.63% from the latest price.

Price Target

$22.51

(16.63% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 3, 2026

Data Sources Report a data error